AESGP annual meeting: OTC switching is all about alli
This article was originally published in Scrip
The centralised EU approval of GlaxoSmithKline's alli (orlistat 60mg) as a non-prescription drug "sets a gold standard for others to follow" in the view of Dr June Raine, director of the post-licensing division of the UK medicines regulatory agency, the MHRA.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.